NFKB1 and prostate carcinoma: Physiological levels of zinc (0.25–0.5 μg/mL) inhibit nuclear factor-kappa B (NF-κB) activities by reducing RelA activity induced by tumor necrosis factor-alpha (TNF-α) and scaling down the expression of cellular inhibitors of apoptosis protein 2 (c-IAP2) in highly invasive androgen-independent DU145 and PC3 prostate cancer cell lines [114].